Johnson & Johnson Acquires Halda Therapeutics for $3.05 Billion
Johnson & Johnson is acquiring clinical-stage biotech Halda Therapeutics for $3.05 billion to enhance its oncology pipeline.
Johnson & Johnson (J&J)
Fujifilm Biotechnologies Opens its Commercial-Scale Cell Culture US Manufacturing Site
Fujifilm Biotechnologies has opened one of North America's largest commercial-scale cell culture biomanufacturing sites in Holly Springs, North Carolina, US.
J&J to Invest $55 Billion in US Operations
US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.
J&J Acquires Rights to Numab's Bispecific Antibody NM26
US healthcare giant Johnson & Johnson (J&J) agreed to acquire Yellow Jersey Therapeutics (YJT) from biotechnology company Numab Therapeutics in an all-cash transaction valued at approximately $1.25 billion, giving it worldwide rights to the novel, investigational bispecific antibody NM26.
Johnson & Johnson and Kenvue Finalize Separation
Kenvue, the world’s largest pure-play consumer health company by revenue and maker of brands such as Band-Aid, Tylenol, Listerine or Neutrogena, eventually became a fully independent company following the final separation from Johnson & Johnson. A stock swap offer to exchange shares of Johnson & Johnson common stock for shares of Kenvue ended at the end of the day on Aug. 18, 2023.
Navigating Uncertainty in the Biopharma Market
Biopharma companies are facing funding challenges in 2023 as interest rates rise and investors are becoming more risk adverse. There is hope on the horizon, say some analysts, while others project a prolonged slump due to inflation and global instability. Established pharmaceutical companies are often seen as safer investments, with larger developers expected to perform well in 2023, especially if litigation threats against drugs like Zantac disappear. However, concerns about revenue gaps continue for big companies like GSK and Sanofi, and their strategy and leadership will be closely monitored in the coming months.
